Quick answer: In 2009, the ITP (Interventions Testing Program) — a multi-institution study funded by the National Institute on Aging — demonstrated that rapamycin, an mTOR inhibitor already in clinical use as an immunosuppressant, extended median lifespan by 9–14% in mice when started at the equivalent of 60 human years of age. This was the first pharmacological intervention to reproducibly extend lifespan in multiple genetic backgrounds of mice, catalyzing a scientific revolution in longevity biology. Today, longevity medicine has moved from theoretical to evidence-based: senolytics clear damaged cells, NAD+ precursors restore mitochondrial function, epigenetic clocks measure biological age, and multiple clinical trials are testing interventions that may slow human aging. Functional longevity medicine synthesizes this science into actionable clinical protocols.
The Hallmarks of Aging: A Framework for Intervention
The 2013 Lopez-Otin framework — expanded to 12 hallmarks in the 2023 Cell update — provides the foundational scientific map of aging biology. These hallmarks are not separate phenomena but an interconnected causal network in which each amplifies the others: genomic instability (accumulation of DNA damage, somatic mutations, mitochondrial DNA deletions); telomere attrition (shortening of chromosome-protective telomeric repeats with each cell division); epigenetic alterations (progressive loss of youthful methylation patterns, histone modification changes); loss of proteostasis (declining ubiquitin-proteasome and autophagy clearance of misfolded proteins, producing the amyloid aggregates of neurodegeneration); deregulated nutrient sensing (AMPK decline, mTOR hyperactivation, IGF-1 pathway dysregulation); mitochondrial dysfunction (decreased biogenesis, increased reactive oxygen species, impaired electron transport efficiency); cellular senescence (permanent cell cycle arrest with inflammatory SASP secretome); stem cell exhaustion (declining regenerative capacity); altered intercellular communication (inflammaging — chronic low-grade sterile inflammation); disabled macroautophagy; chronic inflammation; and dysbiosis.
The therapeutic opportunity within this framework is substantial because multiple hallmarks are addressable with available interventions. Caloric restriction (or its pharmacological mimetics) downregulates mTOR and IGF-1 while activating AMPK and autophagy — addressing four hallmarks simultaneously. Exercise activates PGC-1α-driven mitochondrial biogenesis while stimulating myokine production that reduces senescent cell burden and systemic inflammation. Dietary composition modulates the gut microbiome, insulin sensitivity, and epigenetic methylation patterns. The practical goal of longevity medicine is to achieve the maximal simultaneous intervention across the hallmarks that evidence supports.
Cellular Senescence and Senolytics
Cellular senescence — the state of permanent cell cycle arrest that cells enter in response to DNA damage, telomere shortening, oncogene activation, or oxidative stress — is adaptive in the short term (preventing cancer, facilitating wound healing) but damaging when senescent cells accumulate. Senescent cells secrete the senescence-associated secretory phenotype (SASP): a pro-inflammatory cocktail of cytokines (IL-6, IL-8, IL-1α), growth factors, matrix metalloproteinases, and reactive oxygen species that damage neighboring cells, promote tissue dysfunction, and drive the “inflammaging” that accelerates all other aging hallmarks.
The landmark 2016 study by Baker and colleagues (Nature) demonstrated that genetically clearing senescent cells from naturally aging mice extended median lifespan by 25% and reduced the burden of age-related pathologies including cataracts, muscle wasting, adipose dysfunction, and cardiac hypertrophy. This established cellular senescence as a causal driver of aging phenotypes — not merely a correlate — and validated senescent cell clearance as a therapeutic target.
Senolytics are drugs or compounds that selectively eliminate senescent cells by targeting the pro-survival pathways (BCL-2/BCL-XL, PI3K/AKT) that allow senescent cells to resist apoptosis. The first clinically validated senolytic combination was dasatinib + quercetin (D+Q), identified by Zhu and colleagues (2015, Aging Cell) through a hypothesis-driven screen. Mayo Clinic clinical trials (Kirkland 2019, EBioMedicine) demonstrated that oral D+Q (dasatinib 100mg + quercetin 1,000mg daily for 3 days) reduced senescent cell burden in patients with idiopathic pulmonary fibrosis, with improvements in physical function measures. Multiple clinical trials of D+Q, quercetin alone, navitoclax, and other senolytics are ongoing across diseases including Alzheimer’s, diabetes, kidney disease, and frailty.
Fisetin — a flavonoid found in strawberries, apples, and persimmons — demonstrated impressive senolytic potency in a 2018 EBioMedicine study by Yousefzadeh and colleagues, extending median lifespan by 10% and reducing senescent cell markers more potently than quercetin in multiple mouse tissues. A Phase 2 Mayo Clinic clinical trial (NCT03430037) evaluated fisetin in older adults for senescent cell reduction — preliminary data suggests well-tolerated, with senescence biomarker reductions. Practical senolytic supplementation protocols (“senolytic pulsing”) typically involve quercetin (500–1,000mg) + fisetin (500–1,500mg) for 2–3 consecutive days per month, timing chosen based on the estimated SASP-resolution cycle of senescent cells.
NAD+ Biology: The Mitochondrial Youth Signal
NAD+ (nicotinamide adenine dinucleotide) occupies a uniquely central position in aging biology. It is the essential cofactor for sirtuins (SIRT1–7) — NAD-dependent deacylases that regulate gene expression, mitochondrial biogenesis, DNA repair, and inflammation; for PARP enzymes (poly-ADP ribose polymerases) — NAD-consuming DNA repair enzymes activated by strand breaks; for CD38 — a glycohydrolase that constitutes the primary NAD-consuming enzyme in aging tissues; and for the electron transport chain — through NADH/NAD+ cycling in Complex I.
NAD+ levels decline approximately 50% between ages 20 and 80 in multiple tissues. The primary drivers of this decline are: increased PARP activation from accumulated DNA damage (consuming NAD+); elevated CD38 activity with aging (CD38 increases 2–3-fold in aging tissues); decreased NAMPT (nicotinamide phosphoribosyltransferase) activity — the rate-limiting enzyme in the salvage pathway that regenerates NAD+ from nicotinamide; and increased NAD+ consumption by inflammatory NNMT (nicotinamide N-methyltransferase). This NAD+ decline impairs sirtuin activity, reducing the transcriptional regulation of mitochondrial biogenesis (PGC-1α), DNA repair efficiency, and anti-inflammatory pathways that sirtuins control.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two primary NAD+ precursor supplements in clinical use. Both are precursors in the NAD+ biosynthesis pathway that efficiently raise blood and tissue NAD+ levels. The foundational animal work by Yoshino and colleagues (2011, Cell Metabolism) demonstrated that NMN supplementation reversed multiple metabolic hallmarks of aging in mice — insulin resistance, mitochondrial dysfunction, NAD+ depletion — establishing the proof of concept. Subsequent NMN mouse studies showed improvements in exercise capacity, muscle function, cognitive performance, and longevity.
Human clinical trials have now validated NAD+ elevation with both NMN and NR. Yoshino and colleagues (2021, Science) randomized postmenopausal women with prediabetes to NMN (250mg/day) or placebo for 10 weeks. NMN raised skeletal muscle NAD+ levels, improved insulin signaling (as measured by phospho-AKT response to insulin), and increased muscle gene expression signatures for insulin sensitivity — the first clinical demonstration of NAD+ precursor benefits on a metabolic endpoint in humans. Multiple NR human trials (Martens 2018, Nature Communications) confirm NR raises blood NAD+ by 40–90% at doses of 1,000–2,000mg/day and is well-tolerated. Practical dosing: NMN 500–1,000mg/day or NR 1,000mg/day, ideally in the morning to align with circadian NAD+ rhythms.
mTOR, Rapamycin, and the Nutrient Sensing Axis
mTOR (mechanistic target of rapamycin) is the master nutrient-sensing kinase that integrates signals from amino acids, growth factors, and cellular energy status to coordinate anabolic and catabolic balance. mTORC1 — the rapamycin-sensitive complex — promotes protein synthesis, cell growth, and ribosome biogenesis when active, and suppresses autophagy (cellular self-cleaning) and mitochondrial biogenesis. Chronically elevated mTORC1 in aging tissues — driven by dietary protein excess, insulin resistance, and growth factor signaling — contributes to cellular senescence, protein aggregation, and impaired tissue regeneration.
Rapamycin — an FDA-approved allosteric mTORC1 inhibitor originally developed as an antifungal and immunosuppressant — extends lifespan in every organism tested to date: yeast, worms, flies, and mice. The ITP 2009 results (Harrison 2009, Nature) showed 9% lifespan extension in female mice and 14% in male mice starting at 600 days — equivalent to age 60 in humans. Subsequent ITP studies found lifespan extensions of 10–23% depending on dose and timing. No pharmaceutical intervention has shown comparable, reproducible lifespan extension in mammals.
The clinical use of rapamycin for longevity is among the most actively debated topics in aging medicine, with a growing community of physicians prescribing intermittent low-dose rapamycin (typically 2–6mg once weekly) off-label for healthy aging. The intermittent protocol is designed to achieve mTOR inhibition while minimizing the immunosuppressive and metabolic side effects (impaired wound healing, hyperlipidemia, glucose intolerance) associated with continuous clinical dosing. Joan Mannick and colleagues (2014, Science Translational Medicine) demonstrated that low-dose rapamycin (0.5–5mg/day) improved influenza vaccine responses in elderly individuals by 20% — suggesting immune rejuvenation at doses below classical immunosuppressive thresholds. The PEARL trial, a Phase 2 RCT of rapamycin in healthy older adults, is generating the clinical safety and biomarker data needed to guide clinical recommendations.
Epigenetic Clocks: Measuring Biological Age
Epigenetic clocks — computational models that predict biological age from DNA methylation patterns at specific CpG sites — have transformed longevity research from animal-model-dependent to clinically testable in humans. Steve Horvath’s 2013 clock (Horvath 2013, Genome Biology) demonstrated that DNA methylation age across 353 CpG sites correlated with chronological age across virtually all human tissues with high accuracy (r = 0.96). Critically, biological age measured by this clock predicted all-cause mortality, cardiovascular disease, and cancer incidence independent of chronological age and traditional risk factors.
Second-generation clocks — GrimAge (based on plasma protein predictors), PhenoAge, DunedinPACE — improved predictive accuracy for health outcomes. GrimAge (Lu 2019, Aging) outperforms Horvath’s original clock for mortality prediction, with a 1-year GrimAge acceleration associated with a 15% increase in all-cause mortality. DunedinPACE — developed from longitudinal data following New Zealanders from birth to age 45 — measures the pace of aging (change per calendar year) rather than a static biological age, capturing the dynamic process of biological aging that static methylation patterns may miss.
Commercial biological age testing (through companies including TruDiagnostic, Elysium, and Novo Biosciences) provides actionable clinical data: a patient whose GrimAge exceeds their chronological age by 5+ years warrants aggressive lifestyle and pharmacological intervention; one whose biological age is younger than chronological age provides evidence that their current regimen is working. The goal of functional longevity medicine is to produce measurable GrimAge deceleration and eventually reversal — a target now achievable with aggressive intervention. Fahy and colleagues (2019, Aging Cell) demonstrated 2.5 years of GrimAge reversal in 1 year of combined GH/DHEA/metformin therapy — the first published demonstration of epigenetic age reversal in humans.
AMPK Activation: The Longevity Pathway in Every Cell
AMPK (AMP-activated protein kinase) is the cellular energy sensor that activates longevity-promoting pathways when cellular energy is low (high AMP:ATP ratio) — the precise metabolic state produced by exercise, caloric restriction, and cold exposure. AMPK phosphorylates and activates PGC-1α (driving mitochondrial biogenesis), activates SIRT1 through NAD+ elevation, inhibits mTORC1 (enabling autophagy), activates ULK1 (initiating autophagy directly), and promotes glucose uptake via GLUT4 translocation. In aggregate, AMPK activity recapitulates much of the benefit of caloric restriction at the cellular signaling level.
Berberine activates AMPK through inhibition of mitochondrial Complex I — producing a mild energetic stress that activates the AMPK energy-sensing cascade. This mechanism explains berberine’s multiple metabolic benefits (improved insulin sensitivity, reduced lipogenesis, activated autophagy) through a single molecular target. Berberine’s AMPK activation profile closely resembles metformin — the most widely used diabetes drug, itself an AMPK activator with emerging longevity-research evidence. The TAME (Targeting Aging with Metformin) trial is testing metformin 1,500mg/day as the first pharmacological longevity intervention in a large RCT of non-diabetic older adults.
Urolithin A — produced by gut bacteria from ellagitannins in pomegranate, walnuts, and berries — is an AMPK activator with the additional unique property of directly stimulating mitophagy (selective autophagy of damaged mitochondria) via PINK1/Parkin pathway activation. Ryu and colleagues (2016, Nature Medicine) demonstrated that urolithin A supplementation improved mitochondrial function and exercise capacity in aged animals. Human Phase 2 clinical trials (Andreux 2019, Nature Metabolism) confirmed that urolithin A (500–2,000mg/day) dose-dependently raised skeletal muscle mitophagy markers and improved muscle function in older adults — making it one of the most clinically validated longevity supplements.
Autophagy: The Cellular Recycling System That Slows Aging
Autophagy — the lysosomal degradation pathway that recycles damaged organelles, misfolded proteins, and intracellular pathogens — is a longevity mechanism conserved from yeast to humans. Yoshinori Ohsumi received the 2016 Nobel Prize in Physiology for elucidating autophagy’s molecular machinery. Multiple lines of evidence establish autophagy as a longevity determinant: genetic enhancement of autophagy extends lifespan in worms, flies, and mice; virtually all longevity interventions (caloric restriction, exercise, rapamycin, resveratrol) activate autophagy; and autophagy declines with aging due to reduced AMPK activity, elevated mTOR, and declining TFEB (transcription factor EB, the master autophagy regulator).
The most potent physiological autophagy stimulants are: fasting (AMPK activation, mTOR suppression — autophagy markers rise significantly after 24+ hours of fasting, with meaningful induction beginning around 12–14 hours in ketosis-adapted individuals); exercise (the mechanical and metabolic signals of muscle contraction activate autophagy through AMPK and BNIP3L pathways — one mechanism behind exercise’s longevity benefits); and coffee (independent of caloric content — chlorogenic acids, cafestol, and kahweol activate autophagy through direct AMPK activation and are the proposed mechanism behind coffee’s inverse association with Parkinson’s, Alzheimer’s, and liver cancer in epidemiological studies). Spermidine — found in aged cheese, wheat germ, and soybeans — directly activates autophagy through hypusination of eIF5A and has demonstrated longevity extension in multiple organisms including a 5-year extension in C. elegans.
The Longevity Laboratory Panel
Comprehensive longevity assessment requires biomarkers that track the hallmarks of aging rather than just disease risk factors. Key longevity biomarkers include: biological age (epigenetic clock — ideally GrimAge or DunedinPACE through commercial testing); inflammatory aging markers (hs-CRP below 0.5 mg/L, IL-6, senescence-associated secretory phenotype markers); metabolic health indicators (HOMA-IR below 1.0 for optimal insulin sensitivity, fasting insulin below 5 μIU/mL, HbA1c below 5.4%, continuous glucose monitoring to assess glycemic variability); cardiovascular longevity markers (ApoB, Lp(a), omega-3 index, homocysteine); hormonal longevity indicators (IGF-1, DHEA-S, testosterone, thyroid panel); mitochondrial function proxies (lactate:pyruvate ratio, organic acids panel for TCA cycle function); telomere length (relative or absolute, through specialized testing); and NAD+ metabolomics (blood NAD+ and NAAD through specialized panels).
Frequently Asked Questions
What is biological age and how is it measured? Biological age is an estimate of physiological aging independent of chronological age, measured most accurately through DNA methylation patterns at specific CpG sites (epigenetic clocks). GrimAge — the current gold standard for mortality prediction — was validated in studies showing each year of GrimAge acceleration above chronological age predicts 15% higher mortality. Commercial testing (TruDiagnostic, Elysium, Novos) makes this clinically accessible. Biological age can be younger or older than chronological age — and critically, can be reduced with intervention.
What are senolytics and are they safe? Senolytics are compounds that selectively eliminate senescent cells by targeting their pro-survival pathways. Dasatinib + quercetin is the most clinically studied combination, with Phase 2 trials showing senescent cell reduction in patients with IPF. Quercetin and fisetin are the most commonly used nutraceutical senolytics. Clinical safety data for quercetin and fisetin is favorable from acute supplementation studies. “Senolytic pulsing” — taking senolytics for 2–3 consecutive days per month rather than daily — is the predominant protocol in clinical use, though long-term safety data in healthy humans remains limited.
Does rapamycin extend human lifespan? Rapamycin reproducibly extends lifespan in every animal model tested, including a 9–14% extension in mice started in old age. Human clinical trials have not tested lifespan as a primary endpoint (impractical). However, Mannick 2014 showed low-dose rapamycin improved immune function in elderly humans. Observational data suggests kidney transplant patients on rapamycin have lower cancer rates than those on calcineurin inhibitors. Preclinical and early human data are strongly suggestive, but the risk-benefit calculus for healthy individuals requires individualized assessment given rapamycin’s immunosuppressive properties.
What is the best NMN vs NR supplement for NAD+? Both NMN and NR effectively raise blood and tissue NAD+ levels in human trials. NMN enters cells via a recently discovered NMN transporter (Slc12a8) and may provide more direct cellular NAD+ elevation; NR must be converted to NMN before entering the salvage pathway. Human trials directly comparing the two are limited. Practical considerations: NMN is generally more expensive; NR has more published human trial data (multiple Chromadex-sponsored trials). Either at 500–1,000mg/day for NMN or 1,000mg/day for NR represents a reasonable starting dose, with response monitored via commercial blood NAD+ testing.
Can intermittent fasting slow aging? Intermittent fasting (IF) activates multiple longevity pathways simultaneously: AMPK activation (from fasting-induced ATP depletion), mTOR suppression (enabling autophagy), SIRT1 activation (via rising NAD+), reduction in IGF-1 signaling (from reduced dietary protein), and ketone production (providing HDAC-inhibiting beta-hydroxybutyrate). The CALERIE trial demonstrated that 25% caloric restriction for 2 years reduced biological aging pace in humans (Waziry 2023, Nature Aging). Time-restricted eating (16:8 pattern) produces metabolic benefits with less total caloric restriction, particularly for insulin sensitivity, blood pressure, and inflammatory markers.
Longevity medicine is no longer speculative — it is a rapidly maturing clinical science with actionable interventions supported by robust mechanistic and increasingly clinical evidence. The trajectory of research suggests that meaningful lifespan and healthspan extension is achievable through strategic simultaneous intervention across the hallmarks of aging. Whether you want biological age testing, a comprehensive longevity assessment, discussion of evidence-based interventions from senolytics to NAD+ optimization, or a personalized longevity protocol, The Private Practice offers the clinical depth this frontier medicine demands. Call (810) 206-1402 to schedule your longevity consultation.
Related Articles
- Zone 2 Training & Longevity: The Evidence
- NAD+, NMN & NR Supplements: The Science
- Optimal Vitamin D Levels: What the Research Shows